)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Supernus Pharmaceuticals
Supernus Pharmaceuticals (SUPN) investor relations material
Supernus Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Record Q3 revenue was $226.8M, up 18% YoY; four growth products generated $192.2M, up 29%.
Growth in Qelbree, ONAPGO and ZURZUVAE offset declines in legacy products; Indivior merger closing was expected Nov. 2, 2026.
Financial highlights
Q3 revenue was $226.8M versus $192.1M; 9M revenue was $653.5M versus $507.4M.
Q3 revenue comprised $178.6M product sales, $41.7M ZURZUVAE collaboration revenue and $6.5M royalties, licensing and other revenue.
Q3 total revenue excluding Trokendi XR and Oxtellar XR was $208.6M, up 23%; 9M total was $601.2M, up 37%.
Q3 commercial product revenue was $220.3M, up 17%; 9M total was $599.7M, up 23%.
9M net loss was $39.8M versus $34.4M; 2026 included $56.5M in impairment charges, primarily for APOKYN.
Outlook and guidance
Raised standalone FY 2026 revenue guidance to $875M–$900M from $860M–$890M; adjusted operating earnings guidance rose to $160M–$180M from $150M–$180M.
FY 2026 GAAP operating loss guidance improved to $5M–$40M from $20M–$50M; guidance included ONAPGO sales of $60M–$65M and Trokendi XR/Oxtellar XR sales of $60M–$67M.
Standalone guidance ceases to apply if the merger closes; combined FY 2027 guidance was expected in February 2027.
Management expected future profitability, while noting variability from market pressures, patent erosion, R&D and commercial launch spending.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Supernus Pharmaceuticals
- Supplement revises merger valuation disclosures and highlights litigation and closing risks.SUPN
Proxy filing - Indivior and Supernus to merge as equals, with Supernus shareholders receiving 1.5401 Indivior shares each.SUPNProxy filing
- Qelbree and new launches drive robust growth, with pipeline innovation targeting CNS disorders.SUPNWells Fargo 21st Annual Healthcare Conference
- Qelbree and ONAPGO drive growth as the Indivior merger and innovative pipeline fuel future expansion.SUPN12th Annual Cantor Fitzgerald Global Healthcare Conference
- All-stock merger to form a diversified CNS biopharma leader with $2.2B in commercial assets.SUPNProxy filing
- Merger forms a CNS leader with $2.2B revenue, 11 medicines, and major cost synergies.SUPNProxy filing
- Supernus and Indivior to merge as equals, forming a CNS leader with $2.2B revenue and $1B dividend.SUPNProxy filing
- Merger creates a $2.2B CNS leader with $125M synergies, $1B dividend, and strong growth drivers.SUPNQ2 2026 & Merger
- Strong CNS portfolio growth, robust financials, and expanding market opportunities ahead.SUPNJefferies Global Healthcare Conference 2026
Next Supernus Pharmaceuticals earnings date
Q4 202623 Feb, 2027
Supernus Pharmaceuticals
Next Supernus Pharmaceuticals earnings date
Q4 202623 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Supernus Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system (CNS) disorders. The company specializes in therapies for neurological and psychiatric conditions, including epilepsy, attention deficit hyperactivity disorder (ADHD), and depression. Supernus Pharmaceuticals Inc. is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.